1 nducted to investigate the longevity of this antiadrenergic action after adenosine exposure.

2 le, sotalol and amiodarone, also have potent antiadrenergic actions.

3 large patient sample treated with a powerful antiadrenergic agent.

4             The magnitude of this persistent antiadrenergic effect (PAE) of adenosine at 15 minutes o

5 (w)-nitro-L-arginine methyl ester eliminated antiadrenergic effects of SIL, yet this was not restorab

6                                   Drugs with antiadrenergic effects reduce POAF.

7 fficacy appears to be related importantly to antiadrenergic effects, the mechanism for which has not

8 nt, and L-type calcium current, and exhibits antiadrenergic effects.

9 r restored PDE5A z-band localization and the antiadrenergic efficacy of PDE5A inhibition.

10                                          The antiadrenergic potential of NTG was investigated by exam

11 ial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.

12 2 may, thus, represent a novel intracellular antiadrenergic therapeutic strategy protecting the heart

13 iopathic dilated or ischemic cardiomyopathy, antiadrenergic therapy with beta-blocking agents appears

14  Importantly, there is ample room to improve antiadrenergic therapy, through novel approaches exploit

15  a worse prognosis, and predicts response to antiadrenergic therapy.